© 2025 Inizio Evoke Comms. All Rights Reserved.
Novavax
A New Novavax: Paving the Way in Vaccine R&D
Key Highlights
- R&D Engine Powering Growth following the $1.2 billion deal with Sanofi to Co-commercialize its COVID-19 Vaccine globally and the potential of multiple revenue streams. We are focused on leveraging our proven technology platform by developing early- and late-stage assets through research and development (R&D) and partnering on these assets, as well as our Matrix-M™ adjuvant, with the goal of protecting public health.
- Differentiated Technology Platform: Novavax offers a differentiated vaccine platform that combines its proprietary Matrix-M adjuvant and innovative recombinant, protein-nanoparticle to enhance immune response. Matrix-M uses saponins, naturally occurring compounds in the bark of the Soapbark tree, to help induce a stronger, more potent and longer-lasting immune response. This technology is used in Novavax-developed vaccines and can be licensed out for use in a wider array of vaccines. The nanoparticle helps the immune system recognize a virus from different angles and can provide a greater dose of antigen in a safe and targeted manner.
- Key Events in 2025:
- Continued Progress of Sanofi partnership
- Progress pivotal Phase 3 clinical trials of seasonal influenza and COVID-19-Influenza Combination (CIC) vaccines and continue to work with FDA to assess potential path for accelerated approval
- Progress strategy to identify potential partners and out-licensing opportunities for our technology platform
- Further advance early-stage pipeline, starting with our core of infectious disease and beyond